SUPPLEMENTARY MATERIAL
Western blot analysis
The membranes were blocked in blocking buffer containing 5% skimmed milk in TBST and 3% bovine serum albumin and then incubated overnight at 4 °C with the appropriate antibodies: anti-Alix, anti-TSG101, anti-CD63, anti-MFGE8, anti-CD9
and β-actin (Cell Signaling Technology, Beverly, MA, USA). Horseradish peroxidase-labeled secondary antibodies were added, and the proteins were visualized using an enhanced chemiluminescence kit (BeyoECLPlus, Beyotime, Suzhou, China).
The final results were analyzed using a Gel-Pro Analyzer (Media Cybernetics).
Animal studies
All experiments were performed in strict accordance with the recommendations described in the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. All surgeries were performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. BALB/c-nude mice were purchased from HuaFukang Bioscience Company (Beijing, China). Female mice (6-8 weeks old) were randomly assigned to the different treatment groups. The mice were acclimatized to the Specific Pathogen-Free (SPF) animal housing facility for a minimum period of 1 week before the start of the experiments. The animal housing facility was maintained under well-controlled conditions at a constant temperature (22 ± 2 °C) and humidity (55 ± 5%) and with a 12 h/12 h light/dark cycle. The animals were provided access to food and water ad libitum.
Briefly, RPMI8226 cells in log-phase growth were aspirated into a 50 μL
Hamilton syringe (Alltech Associates) that was coupled to a 27-gauge needle. The Finally, the slices were mounted in neutral gum prior to microscopic examination, and the cells containing brown granules in the cytoplasm or nucleolus were considered to be positive. All analyses were performed using an Olympus CX41 microscope.
CirEV counting and detection
Forward-scatter (FSC) and side-scatter (SSC) light were set on a logarithmic scale, and the fluorescence channels were set for logarithmic gain. Calibration beads were used to set the EV gate (using 1 μm beads) and to calculate the cirEV counts (using 3 μm beads). The EVs were further stained with calcein-AM. The cirEVs were defined as particles < 1.0 μm in diameter that exhibited calcein-AM-positive staining. After the particles were labeled with calcein-AM for 25-30 min in the dark, individual cirEV samples were diluted to a final volume of 300 μL. Then, calibration beads (3 μm diameter in 0.5 μL) were added immediately before the analysis. The gain settings were adjusted to place the 3 μm bead in the top right corner for scatter. Data acquisition was stopped when the number of events in the 3 μm bead gate reached 100,000. The counts for the cirEVs were calculated using a previously published equation [5] .
Individual samples of isolated cirEVs (100 μL) were incubated with a mixture of antibodies against the surface markers and calcein-AM for 25-30 min in the dark.
Additionally, fluorescence minus one controls were prepared for each marker to reveal the boundary between the positively and negatively labeled EVs [6] . After the cells were incubated, the volume was expanded to 300 μL. Before the flow cytometry analysis was performed, the mixture was vortexed for 20 s. Fluorescent cross-talk was controlled using compensation adjustments. Kruskal-Wallis test were used to calculate the differences in the cirEV counts across the patients with bone lesions who were divided into two (≤ 3 and > 3) and three (0, ≤ 3 and > 3) groups, respectively. The Kruskal-Wallis test was used to compare the cirEV counts between the de novo patients with different levels of β2-MG or different Ig types. Correlations between the cirEV counts and multiple serum factors or BMPC% were calculated using the Spearman's correlation test. ROC curves were used to determine the sensitivity, specificity, and positive and negative predictive values. amp(1q21), t(4;14) and an adverse IGH translocation in de novo MM patients.
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Difference in the levels of PB CD138 + EVs between patients with (n = 15) and without
6
(n = 10) the detected lesions (A), with less than or equal to one lesion (n = 15) and 7 with more than one lesion (n = 10) (B), with (n = 12) and without (n = 13) amp(1q21) 8 (C), with (n = 12) and without (n = 13) t(4;14) (D), with (n = 9) and without (n = 16) 9 del(13q14.3) (E), and with (n = 14) and without (n = 11) an adverse IGH translocation(F). 
